BridgeBio Pharma Inc (BBIO) is a Healthcare · Biotechnology company listed on NASDAQ. Price $67.11 (-0.30%), Market cap $12.93B, 52-week low–high $32.26 ~ $79.91.
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops
Financial statements, price targets, institutional (13F) holdings and related news for BridgeBio Pharma Inc are updated in real time on BlackAll Trade.
BridgeBio Pharma Inc trades at $67.11 (-0.30%). Real-time quotes and charts are available on BlackAll Trade.
BridgeBio Pharma Inc has a market cap of about $12.93B.
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule n